Skip to nav Skip to content

Clinical Trial Search

302 Clinical Trials Found

Clinical Trial 21518

A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation Positive Solid Tumors
Disease Site: Any Site
PI: Kim, Richard

Clinical Trial 90016

Disease Site: Other Hematopoietic
PI: Sandoval-Sus, Jose

Clinical Trial 19722

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Disease Site: Multiple Myeloma
PI: Alsina, Melissa

Clinical Trial 21894

Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer {NMIBC)
Disease Site: Urinary Bladder
PI: Poch, Michael

Clinical Trial 21193

Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 21459

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Disease Site: Colon
PI: Imanirad, Iman

Clinical Trial 20894

Acalabrutinib for Chronic Graft-versus-Host Disease
Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 21996

Disease Site: Other Skin
PI: Khushalani, Nikhil

Clinical Trial 22102

A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Disease Site: Breast, Other Female Genital, Ovary
PI: Han, Heather

Clinical Trial 22325

A Phase 1 Study of Irreversible Electroporation and Pembrolizumab Immunotherapy in Locally Advanced Pancreatic Cancer
Disease Site: Pancreas
PI: Malafa, Mokenge

Clinical Trial 22199-C

TACTIVE-U: An Interventional Safety and Efficacy Phase 1b/2, Open-Label Umbrella Study to Investigate Tolerability, PK, and Antitumor Activity of Vepdegestrant (ARV-471/PF-07850327), an Oral Proteolysis Targeting Chimera, in Combination with Other Anticancer Treatments in Participants Aged 18 and Older with ER+ Advanced or Metastatic Breast Cancer, Sub-Study C (ARV-471 in Combination with Samuraciclib)
Disease Site: Breast
PI: Han, Heather